Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Rania S. Khelifi, Steven J.T. Huang, BMLSc, Kerry J. Savage, MDMSc, Diego Villa, MDMPH, David W. Scott, MBChB, PhD, Khaled Ramadan, MBBCH, MRCP, FRCPath, Joseph M. Connors, MD, Laurie H. Sehn, MDMPH, Cynthia L Toze, MD FRCPC, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138887

Published: 2020

Journal Articles

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Sarah E. Perry, MD MSc, Derrick G. Lee, PhD, Ciara L. Freeman, MSc, MBBChir, Diego Villa, MDMPH, Alina S. Gerrie, MD MPH, Pedro Farinha, MD PhD, Jeffrey W. Craig, MD PhD, Graham W. Slack, MD, Joseph M. Connors, MD, David W. Scott, MBChB, PhD, Kerry J. Savage, BSc, MD MSc, Laurie H. Sehn, MDMPH

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136457

Published: 2020

Journal Articles

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

Kai Zhu, Andrew Jamroz, Bsc, Steven J.T. Huang, BMLSc, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Graham W. Slack, MD, Laurie H. Sehn, MDMPH, Joseph M. Connors, MD, Cynthia L. Toze, MDFRCPC,MSc, Kerry J. Savage, MDMSc, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-141183

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-137089

Published: 2020

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Kristin C. Marr, MD, Jonathan Simkin, MPH, Andrea C. Lo, MD, Joseph M. Connors, MD, Alina S. Gerrie, MD MPH, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Greg Hapgood, BMBS, FRACP, FRCPA, Laurie H. Sehn, MDMPH, Ryan Woods, MSc PhD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136454

Published: 2020

Journal Articles

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD, David W. Scott, MBChB, PhD, Diego Villa, MD FRCPC, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Pedro Farinha, MD PhD, Graham W Slack, MD PhD, Don Wilson, MD, R. Petter Tonseth, MD, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 401.

https://doi.org/10.1182/blood-2019-128722

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Blood (2018) 132 (Supplement 1): 921.

https://doi.org/10.1182/blood-2018-99-116827

Published: 2018

Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD

Blood (2018) 132 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2018-99-111278

Published: 2018

Journal Articles

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2018-99-112010

Published: 2018

Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood (2018) 132 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2018-99-112178

Published: 2018

Journal Articles

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won-Seog Kim, Ranjana H Advani, MD, Nancy L. Bartlett, MD, David J. Straus, MD, Anna Sureda, MD, Martin Hutchings, MD PhD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, John Radford, MD FRCP

Blood (2018) 132 (Supplement 1): 2904.

https://doi.org/10.1182/blood-2018-99-118828

Published: 2018

NARROW

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only